Reversibility of Platelet Thrombosis In Vivo

Summary

Reversibility in vivo of acute platelet thrombosis in response to specific anticoagulants is analyzed with thrombi that develop in segments (1 cm) of porcine carotid arteries externally crushed with a hemostat. Most thrombi fill the lumens of the injured segments (ca. 1 cm × 3 mm, 1 × w) within 30 min and comprise masses of platelets interpenetrated with neutrophil-lined seepage channels of blood. Continuous quantitative assay of thrombus mass is provided by a gamma detector placed over the injured segments to collect counts from ¹¹¹In-labeled platelets. Thrombi established 30 min after injury, otherwise stable for 6 h, clear during 30-60 min of continuous infusion of either hirudin, tick anticoagulant or activated porcine protein C, or intermittent activation of endogenous protein C with a latent thrombin reagent. Anticoagulant dose-dependence of thrombus clearance is established for hirudin between 0.01 and 1.0 mg/kg/min. Thrombi become progressively refractory to hirudin between 0.5 and 6 h after injury. Neither heparin nor low-molecular-weight heparin in full (clinical) anticoagulant doses yield significant dethrombosis. It is concluded that, within time limits, controlled thrombin generation in platelet thrombi maintains platelet cohesion without catalyzing irreversible platelet aggregation or clotting of fibrinogen.

• References

• 1 Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR. Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. Blood 1984; 63: 1004-1014
• 2 Heras M, Chesebro JH, Webster MW, Murk JS, Grill DE, Penny WJ, Bowie EJW, Badimon J, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-1484
• 3 Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-2012
• 4 Jang IK, Gold HK, Ziskind AA, Leinback RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990; 81: 219-225
• 5 Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arteriosclerosis & Thrombosis 1994; 14: 1466-1474
• 6 Smirnov MD, Pyzh MW, Borovikov DV, Atorozhilova AH, Dobrovolski AB. Low doses of activated protein C delay arterial thrombosis in rats. Thromb Res 1990; 57: 645-650
• 7 Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM, Willerson JT. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27
• 8 Reimers HJ, Buchanan MR, Mustard JF. Survival of washed rabbit platelets in vivo. Proc Soc Exp Biol Med 1973; 142: 1222-1225
• 9 Reimers HJ, Packham MA, Kinlough-Rathbone RL, Mustard JF. Effect of repeated treatment of rabbit platelets with low concentrations of thrombin on their function, metabolism and survival. Brit J Haematol 1973; 25: 675-689
• 10 Owen WG, Bichler J, Erickson D, Wysokinski W. Gating of platelet function by pO₂-linked lowering of extracellular Ca²⁺ . Biochemistry 1995; 34: 9277-9281
• 11 Wallis RB. The effect of recombinant hirudin on arterial thrombosis. Adv Exp Med Biol 1993; 340: 237-321
• 12 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596
• 13 McBane RD, Wysokinski W, Chesebro JH, Owen WG. Antithrombotic action of endogenous protein C activated with a latent thrombin preparation. Thromb Haemost 1995; 74: 879-885
• 14 Lollar P, Knutson GJ, Fass DN. Stabilization of thrombin-activated porcine factor VIII:C by factor IXa and phospholipid. Blood 1984; 63: 1303-1308
• 15 Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta 1979; 517: 333-342
• 16 Poliak J. Peripheral Vascular Sonography. Williams and Wilkins, Baltimore 1992; 1-47
• 17 Folts JD. An in vivo model of experimental arterial stenosis, intimal damage and periodic thrombosis. Circulation 1991; 83 suppl (Suppl. 04) 3-14
• 18 Jorgensen L, Rowsell H, Hovig T, Mustard JF. Resolution and organization of platelet-rich mural thrombi in carotid arteries of swine. Am J Path 1967; 51: 681-719
• 19 Van Aken PJ, Emeis JJ. Organization of experimentally induced arterial thrombosis in rats: the first six days. Artery 1982; 11: 156-173
• 20 Butler KD, Ambler J, Dolan S, Giddings J, Talbot MD, Wallis RB. A non-occlusive model of arterial thrombus formation in the rat and its modification by inhibitors of platelet function or thrombin activity. Blood Coag Fibrinol 1992; 3: 155-165
• 21 Parise P, Agnelli G. Thrombus resistance to lysis and reocclusion after thrombolysis: the role of platelets. Blood Coag Fibrinol 1991; 2: 749-758 (rev)
• 22 Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis. Blood 1989; 74: 1025-1030
• 23 Rudd MA, George D, Johnstone MT, Moore RT, Collins L, Rabbani LE, Loscalzo J. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circ Res 1992; 70: 829-834
• 24 Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis Circulation 1992; 85: 805-815
• 25 Mruk JS, Zoldhelyi P, Webster MWI, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus. Circulation 1996; 93: 792-799
• 26 Kieffer N, Phillips DR. Platelet membrane glycoproteins: function in cellular interactions. Ann Rev Cell Biol 1990; 69: 11-25
• 27 Repke D, Gemmell CH, Guha A, Turitto VT, Broze Jr GJ, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Nat Acad Sci 1990; 87: 7623-7627
• 28 Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J Clin Invest 1983; 71: 1383-1391
• 29 Krishnaswami S, Vlasuk GP, Bergum PW. Assembly of prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 1994; 33: 7897-7907
• 30 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 31 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Nat Acad Sci 1989; 86: 3619-3623
• 32 Lenfors S, Marberg L, Wikstrom S, Jonsson U, Westin-Eriksson A, Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: thrombolysis experiments with specific thrombin inhibition. Blood Coag Fibrinol 1993; 4: 263-271